scholarly article | Q13442814 |
P50 | author | Anuradha Chowdhary | Q42337778 |
David S Perlin | Q104479284 | ||
P2093 | author name string | Yanan Zhao | |
Steven Park | |||
Annie Lee | |||
Milena Kordalewska | |||
Indira Berrio | |||
P2860 | cites work | Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint | Q42545839 |
Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. | Q42687352 | ||
Candida auris-associated candidemia, South Africa | Q42712931 | ||
Candida auris candidemia in Kuwait, 2014. | Q42787996 | ||
Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features | Q43521723 | ||
Candidemia caused by amphotericin B and fluconazole resistant Candida auris | Q44304263 | ||
Optimized 5-hour multiplex PCR test for the detection of tinea unguium: performance in a routine PCR laboratory. | Q45234129 | ||
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. | Q50083987 | ||
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris | Q50145270 | ||
Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013-August 2016. | Q50985111 | ||
Candida auris for the clinical microbiology laboratory: Not your grandfather's Candida species. | Q53704744 | ||
Hospital transmitted Candida auris infections confirmed in the US. | Q53762019 | ||
Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy | Q81739235 | ||
Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia | Q28818814 | ||
Multidrug-resistant Candida auris: 'new kid on the block' in hospital-associated infections? | Q30245326 | ||
Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital | Q33401940 | ||
Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally | Q33704302 | ||
First three reported cases of nosocomial fungemia caused by Candida auris | Q34196357 | ||
New clonal strain of Candida auris, Delhi, India | Q34372060 | ||
First hospital outbreak of the globally emerging Candida auris in a European hospital | Q34543358 | ||
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses | Q34547546 | ||
New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species | Q35139501 | ||
Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek | Q35586995 | ||
Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. | Q35835357 | ||
Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods | Q36022880 | ||
How to calculate sample size in animal studies? | Q37303624 | ||
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? | Q37335747 | ||
Current perspectives on echinocandin class drugs | Q37554055 | ||
Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel | Q37664411 | ||
The Eagle-like effect of echinocandins: what's in a name? | Q38153458 | ||
Mechanisms of echinocandin antifungal drug resistance | Q38550402 | ||
Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. | Q39092102 | ||
Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. | Q39092125 | ||
First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia | Q39092138 | ||
Incidence, characteristics and outcome of ICU-acquired candidemia in India | Q39092143 | ||
Multidrug-resistant endemic clonal strain of Candida auris in India. | Q39092162 | ||
Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris | Q39092215 | ||
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection | Q39092240 | ||
The first cases of Candida auris candidaemia in Oman | Q39092264 | ||
Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. | Q39092317 | ||
Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variation | Q39092330 | ||
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. | Q39657947 | ||
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations | Q39954432 | ||
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints | Q41787736 | ||
Isolation of Candida auris from nine patients in Central America: Importance of accurate diagnosis and susceptibility testing | Q41994530 | ||
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae | Q42035911 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | Candida auris | Q26816853 |
emerging pathogen | Q108429945 | ||
P577 | publication date | 2018-04-09 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Understanding echinocandin resistance in the emerging pathogen Candida auris. |
Q90618019 | Antifungal Resistance: Specific Focus on Multidrug Resistance in Candida auris and Secondary Azole Resistance in Aspergillus fumigatus |
Q92320618 | Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris |
Q64270951 | Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA Sequencing for a Wide Range of Clinically Isolated Yeast Species: Improved Identification by Combining 21-Plex PCR and API 20C AUX as an Alternative Strategy for Developing Countries |
Q90572938 | Detection of Candida auris antifungal drug resistance markers directly from clinical skin swabs |
Q89665271 | Drug resistance and tolerance in fungi |
Q99709014 | Echinocandins as Biotechnological Tools for Treating Candida auris Infections |
Q92376812 | Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen |
Q58598193 | Epidemiology, clinical characteristics, resistance, and treatment of infections by |
Q96155834 | Genetic Heterogeneity of Australian Candida auris Isolates: Insights From a Nonoutbreak Setting Using Whole-Genome Sequencing |
Q64226654 | Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS |
Q93088245 | Identification of Drug Resistant Candida auris |
Q64084323 | Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen |
Q58693906 | MALDI-TOF MS Applications to the Detection of Antifungal Resistance: State of the Art and Future Perspectives |
Q92752608 | Molecular Diagnostics in the Times of Surveillance for Candida auris |
Q92666321 | Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen |
Q91623044 | Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm |
Q58609308 | Rapid Detection of ERG11-Associated Azole Resistance and FKS-Associated Echinocandin Resistance in Candida auris. |
Q92071802 | Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris |
Q93166142 | Something wicked this way comes: What health care providers need to know about Candida auris |
Q64070550 | The global challenge of Candida auris in the intensive care unit |
Q94451620 | Tracing the Evolutionary History and Global Expansion of Candida auris Using Population Genomic Analyses |
Q55689919 | Transcriptome Assembly and Profiling of Candida auris Reveals Novel Insights into Biofilm-Mediated Resistance. |
Q90204317 | Translation Inhibition by Rocaglates Activates a Species-Specific Cell Death Program in the Emerging Fungal Pathogen Candida auris |
Search more.